Phibro Animal Health Corporation announced its financial results for the fourth quarter and full fiscal year ended June 30, 2025. For the fourth quarter, the company reported a robust 39% increase in revenue compared to the prior year. Net income for the quarter was $17.2 million, with diluted earnings per share of $0.42.
For the full fiscal year 2025, Phibro achieved total revenue of $1.30 billion, representing a 27% increase from fiscal year 2024. This growth was primarily driven by strong sales in the Animal Health segment and the strategic acquisition of the Zoetis Medicated Feed Additive portfolio.
The company provided a positive outlook for fiscal year 2026, anticipating continued growth. This outlook is supported by the full integration of the acquired Zoetis portfolio and ongoing benefits from the Phibro Forward income growth initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.